The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
== CFNA (alternative to Mosher's acid) == A newer chiral derivatizing agent (CDA), α-cyano-α-fluoro (2-naphthyl)-acetic acid (2-CFNA) was prepared in optically pure form by the chiral HPLC separation of a racemic 2-CFNA methyl ester. This ester was obtained by fluorination of methyl α-cyano (2-naphthyl) acetate with FClO3. 2-CFNA has been shown to be a superior CDA than Mosher's agent to determine the enantiomeric excess of a primary alcohol.
The LAL test is a major source of animal product dependence in the biomedical industry, and a challenge to the Three Rs of science in relation to the use of animals in testing. With reports of higher-than anticipated mortality rates it has been considered more ethical to devise alternatives to the test. Since 2003, a recombinant protein substitute for use in the LAL test has been commercially available. Named the recombinant factor C (rFC) assay, it is based on the same Limulus clotting factor C protein, but produced by genetically modified insect cells (the specific factor C sequence used does not necessarily come from the Atlantic horseshoe crab). Instead of emulating the whole clotting pathway, rFC tests let factor C cleave a synthetic fluorogenic substrate, so that the sample lights up when endotoxin activates the factor. Since it does not contain factor G, (1,3)-β-D-glucan will not cause false-positives. As of 2018, available evidence shows that the rFC test is no worse than the LAL test. The adoption of the rFC test was slow, which began to change in 2012 when the US FDA and the European health ministry acknowledged it as an accepted alternative. Its lack of mention in Pharmacopeias remained an issue, as there was no good standard for running the test in production. In 2016, it was added to the European Pharmacopoeia. A patent on rFC also limited adoption until its expiration in 2018.
== History == 4-HO-MET was first synthesized and discovered by Alexander Shulgin in the 1970s. It was first described in the scientific literature by David Repke and colleagues by 1981. Subsequently, 4-HO-MET was described by Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved) in 1997 as being- aside from its synthesis- indistinguishable from any other ethyl homologue. It was encountered as a novel recreational and designer drug in Europe by 2008 and recently in the United States in 2025.
=== Russia and Ukraine === From 2013 to 2022 Galloway was a presenter on the Russian state-controlled television network RT. Galloway called the 2014 Ukrainian Revolution a Western-backed "coup" and a "foreign financed invasion of the sovereignty of Ukraine". He believes Russia's annexation of Crimea was legitimate, because he said the disputed 2014 Crimean status referendum showed that "the huge majority of people in Crimea wanted to leave Ukraine". In a 2016 interview of Nigel Farage, Galloway said "I respect Putin and I think he's very popular in Russia". When Russian opposition leader Alexei Navalny was poisoned in August 2020, Galloway claimed on RT that Navalny was a white supremacist. In early 2022, Galloway dismissed claims that Russia was about to invade Ukraine, writing "I told you it wasn't. You were wrong. I was right". When Russia invaded Ukraine ten days later, he said the invasion was "not what I wanted", but he blamed the invasion on "the West" and accused it of "Pumping Ukraine full of NATO weapons, mercenaries and propaganda". He suggested that the Bucha massacre was staged. Galloway was accused of being an apologist and propagandist for Russian president Vladimir Putin by the larger political parties. Jamie Blackett ended their political alliance All for Unity over their disagreement on Ukraine. The Scottish Liberal Democrats leader, Alex Cole-Hamilton, called Galloway "an apologist for Russian expansionist aggression" and said that Galloway's "association with RT has lent legitimacy and influence to the propaganda apparatus of a hostile power".
Sources: en.wikipedia.org
Analysis of mitochondrial DNA by German herpetologist Wolfgang Wüster and colleagues in 2005 found the Papuan and nominate subspecies to be very similar genetically; however, their distinct coloration and limited sampling led Wüster to refrain from lumping the subspecies into a single taxon. Raymond Hoser described Oxyuranus scutellatus barringeri from a specimen collected from the Mitchell Plateau, however Wüster declared this a nomen nudum as the author did not explain how it was distinct. Hoser replied that it was distinct on the basis of DNA and distribution, and published it under a different subspecific name—O. scutellatus andrewwilsoni—in 2009, reporting it had a more rounded head and rougher neck scales than other subspecies of coastal taipan, and lacked a lighter colour on the snout. Kinghorn gave it the name "giant brown snake" in 1930, before Thomson introduced the term taipan in 1933. It is commonly called the coastal taipan, common taipan, or simply taipan. The New Guinea subspecies is known as the Papuan taipan. Local names in New Guinea include dirioro by the people of Parama village near the Fly River, and gobari near the Vailala River.
These imperatores (lit: victorious generals, from the title imperator they were hailed with by their troops) frequently fell out with each other and started civil wars to seize control of the state, such as Sulla, Caesar, Pompey, Crassus, Mark Antony and Octavian (later Augustus, the first Emperor himself). In this context, the imperatores raised many legions that were not authorised by the Senate, sometimes having to use their own resources. As civil wars were resolved, many of these "private" units would be disbanded, only for more to be raised to fight the next civil war. By the time Augustus emerged as sole ruler of Rome in 31 BC, over 50 legions were in existence, many of which were disbanded. The legions included in the following list had a long enough history to be somehow remarkable. Most of them were levied by Julius Caesar and later included into Octavian's army, some of them were levied by Mark Antony.
=== Lactic acidosis === A randomized controlled trial in children with congenital lactic acidosis found that while DCA was well tolerated, it was ineffective in improving clinical outcomes. A separate trial of DCA in children with MELAS (a syndrome of inadequate mitochondrial function, leading to lactic acidosis) was halted early, as all 15 of the children receiving DCA experienced significant nerve toxicity without any evidence of benefit from the medication. A randomized controlled trial of DCA in adults with lactic acidosis found that while DCA lowered blood lactate levels, it had no clinical benefit and did not improve hemodynamics or survival. Thus, while early case reports and pre-clinical data suggested that DCA might be effective for lactic acidosis, subsequent controlled trials have found no clinical benefit of DCA in this setting. In addition, clinical trial subjects were incapable of continuing on DCA as a study medication owing to progressive toxicities.
=== Monoamine oxidase inhibitors === It is unclear whether mescaline is metabolized by monoamine oxidase (MAO) enzymes or whether monoamine oxidase inhibitors (MAOIs) might increase the effects of mescaline. No clinical studies of mescaline in combination with MAOIs are known to have been published. However, there are preliminary reports that harmala alkaloids, which are reversible inhibitors of monoamine oxidase A (RIMAs), may potentiate the effects of mescaline in humans, and the combination of mescaline or mescaline-containing cacti with harmala alkaloids has been referred to as "peyohuasca". In accordance with these findings, the harmala alkaloid and RIMA harmine has been reported to augment the effects of mescaline in animals. On the other hand, Daniel Trachsel has stated that mescaline is not metabolized by MAO, instead being metabolized by semicarbazide-sensitive amine oxidase (SSAO), and hence that MAOIs that do not also inhibit SSAO should have no effect on the metabolism of mescaline. Accordingly, the MAOI iproniazid did not potentiate the behavioral effects of mescaline in rats.
=== Gas chromatography with mass spectrometry (GC-MS) === Gas chromatography with mass spectrometry (GC-MS) is considered the gold standard for VOC analysis to identify specific compounds. The chromatography separates the sample mixture in a gaseous state by forcing them through a column using a carrier gas, and the mass spectrometer identifies the compound. The limitation of this method is the requirement of expensive specialized equipment and highly trained personnel. VOC analysis is seen in asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), chronic obstructive sleep apnea (OSA), inflammatory bowel disease, cancer, infections, and among others.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.